FREE Shipping on all US Orders
From Root to Ritual
Ingredient spotlight: black seed oil — thymoquinone, the COX-2/PGD2 mechanism, and the honest evidence picture for a widely promoted natural remedy.
Black seed oil (Nigella sativa) contains thymoquinone — a compound
that inhibits COX-2 and reduces prostaglandin D2 (PGD2), an
inflammatory molecule elevated in balding scalps. A 2014 RCT found
significant improvement in hair density and thickness for telogen
effluvium patients using a topical Nigella sativa lotion vs placebo.
The honest limitation: most other evidence is small, short, or
animal-based. The evidence for AGA specifically is thin. The
anti-inflammatory mechanism is its strongest contribution. Here is
the complete picture.
The $26 million hair growth injectable that started with a hairy mole — Amplifica's osteopontin discovery, the Phase 1 results, and what Eli Lilly's participation signals.
Amplifica Holdings Group closed an oversubscribed $26 million Series B
on August 12, 2026 — with Eli Lilly as a strategic investor. The
science begins with hairy moles: UCI professor Maksim Plikus discovered
that senescent pigment cells in moles produce osteopontin, a signalling
molecule that reactivates dormant hair follicle stem cells. AMP-303
— Amplifica's lead injectable candidate — completed a Phase 1 RCT
(September 2024) showing statistically significant >15% increase in
non-vellus hair count at 60 days (p<0.001) vs placebo. This is early
but genuinely interesting. Here is the complete honest picture.
Post-COVID hair loss: four biological pathways, one clinical picture — and why the long COVID variant is a different problem from the acute infection one.
A 2024 multi-centre cross-sectional study of 500 female COVID-19
patients found 61.4% experienced some form of hair problem after
infection — telogen effluvium accounting for the majority. A
COVID-19 Long Haul Foundation review (May 2026) identified four
biological pathways: cytokine-driven TE, vascular injury to follicle
supply, hypoxic stress from illness severity, and immune privilege
collapse at the hair bulb. Most post-acute COVID hair loss resolves
within 6-9 months without treatment. Long COVID hair loss is a
different and more persistent problem. Here is the complete guide.
When the immune system turns on your hair: autoimmune conditions, hair loss mechanisms, and what a 2025 gut-skin discovery changes about how we investigate alopecia areata.
More than 80 autoimmune diseases exist — and hair loss features in
many of them through five distinct mechanisms: direct follicle attack
(alopecia areata), systemic inflammation-driven TE, hormone disruption
(Hashimoto's, Graves'), medication-induced TE, and scarring from
cutaneous autoimmune lesions (discoid lupus). A paper published
August 25, 2025 in JAAD (University of California, Irvine) found an
unexpected connection between microscopic colitis and alopecia areata —
suggesting the gut-skin axis is more directly relevant to AA than
previously understood. Here is the complete honest guide.
Frontal fibrosing alopecia: the fastest-growing scarring alopecia globally — what it is, why it's increasing, and the sunscreen hypothesis the experts are still debating.
Frontal fibrosing alopecia (FFA) is a progressive scarring alopecia
that has increased steadily in prevalence since its first description
in 1994. It primarily affects postmenopausal women — presenting as
frontal hairline recession, eyebrow loss, and facial papules. The SOFFIA
2024 international consensus statement (69 experts, 6 continents,
published JEADV July 2025) is the most authoritative current guidance.
The Spanish expert panel (January 2025) recommends avoiding organic
UV filters and benzyl salicylate in cosmetics. The JAAD April 2026
management review outlines current treatment approaches. Here is the
complete honest picture — what FFA is, how it differs from other
scarring alopecias, and the environmental trigger debate.
Azelaic acid and hair loss: what the 2023 minoxidil comparison study found — and the honest gap between interesting evidence and proven treatment.
A 2023 study of 26 women with mild female pattern hair loss compared
5% azelaic acid to 2% topical minoxidil twice daily for six months —
both significantly improved hair density and thickness with no
statistically significant difference between them. A 2015 study found
minoxidil plus azelaic acid plus tretinoin outperformed minoxidil alone.
The honest picture: the mechanism traces to a 1988 in vitro study,
human trials are small, and azelaic acid is not a licensed hair loss
treatment. A 2026 clinical trial is now testing it specifically for
CCCA. Here is the complete evidence review.
What nobody tells you about the patience that hair recovery actually requires.
Three months.
That is how long the telogen phase lasts. Three months between a follicle entering rest and the hair it was holding shedding. Thre...
How to actually read a hair care ingredient label — the INCI system, what the order means, what to avoid, and why "natural" means nothing.
Every hair care product is required to list its ingredients by
concentration — highest to lowest — using the INCI (International
Nomenclature Cosmetic Ingredient) system. The first five ingredients
make up the majority of the formula. "Natural" is unregulated and
meaningless. "Sulfate-free" doesn't mean fragrance-free or paraben-free.
Fragrance can legally hide dozens of undisclosed compounds. This article
is the two-minute guide to reading any hair care label with confidence —
what the system is, what to look for, what to avoid, and the six
marketing claims that tell you nothing.
Hair loss in your 20s and 30s: why it is happening earlier than expected — and the four causes most likely to be driving it.
A 2024-2025 study of 390 AGA patients found mean onset age was
23.9 years in men and 29.46 years in women. 25% of men show
first signs before age 21. Over 10% of premenopausal women
show pattern hair loss evidence before 40. Early-onset hair
loss in the 20s and 30s has four primary drivers — early-onset
AGA, telogen effluvium from nutritional deficiency or stress,
PCOS-driven androgenic loss, and traction alopecia. Each has
a different investigation and approach. The earlier the correct
driver is identified, the more follicles can be preserved.
Ingredient spotlight: hibiscus — two species, two different evidence stories, and why the one in your hair products is different from the one in your tea.
There are two distinct hibiscus species relevant to hair and skin care —
Hibiscus rosa-sinensis (the ornamental tropical hibiscus, used topically
for hair) and Hibiscus sabdariffa (roselle, used as a hydrosol and
extract for antioxidant and anti-inflammatory activity). Their evidence
profiles are completely different. Rosa-sinensis has animal studies
showing 5-AR inhibition and anagen promotion — but no large human RCT.
Sabdariffa has strong antioxidant, elastase-inhibiting, and AHA evidence
confirmed in multiple studies. The Laritelle formulas use sabdariffa
hydrosol. Here is the complete honest picture of both.
The mind-body connection and hair loss: what psychoneuroimmunology actually confirms — three molecular pathways, one honest picture.
A JAAD Reviews paper published October 2025 synthesised the current
evidence on psychological stress and hair follicle dysfunction —
identifying three molecular pathways: the HPA axis/cortisol/Gas6
suppression pathway, a newly elucidated CRH-PTEN-autophagy pathway
(Annals of Medicine, April 2025), and the substance P neurogenic
inflammation pathway. A 2025 data analysis of over one million hair
loss cases found high stress increased odds of sudden hair shedding
by approximately 1.5 times. Women with high stress were approximately
11 times more likely to experience hair loss. Here is the complete
honest picture — what the research confirms, what it overstates,
and what actually helps.
Male androgenetic alopecia: the Norwood scale, the biology, and the honest non-prescription evidence — from a 2025 network meta-analysis of OTC treatments.
Male androgenetic alopecia affects approximately 50 million men in
the United States — 85% of men will experience it by age 50. A 2025
Bayesian network meta-analysis (MDPI, Int J Mol Sci, published August
16, 2025) compared nine non-prescription OTC treatments for male AGA
at 24 weeks. A 2025 network meta-analysis confirmed finasteride plus
minoxidil adds 29.68 hairs/cm² — the most efficacious non-surgical
protocol. The Norwood scale stages I-VII determine which intervention
is most appropriate. Here is the complete honest guide — biology,
staging, and the non-prescription evidence ranked by the 2025 data.